Allogeneic transplantation for Hodgkin's lymphoma (Q37820685)

23 August 2017

1 reference

title

Allogeneic transplantation for Hodgkin's lymphoma (English)

1 reference

23 August 2017

3

0 references

Paolo Corradini

series ordinal

1

0 references

author name string

Barbara Sarina

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

13 December 2010

1 reference

British Journal of Haematology

23 August 2017

published in

1 reference

23 August 2017

volume

152

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

261-272

1 reference

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Bone marrow microenvironment and tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Treatment advances in posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Molecular biology of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: A two centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08492.X

10.1111/J.1365-2141.2010.08492.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference